文献速递妇科

晚期卵巢癌减瘤手术与辅助化疗间隔与总生存期相关

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-07-09

本研究基于荷兰癌症登记处2008至2015年数据,纳入4097例接受满意或完全减瘤手术的原发性晚期上皮性卵巢癌(FIGO IIb-IV期)患者,其中初次减瘤手术1612例、中间减瘤手术2485例。手术至辅助化疗时间(TTC)中位29天(IQR 24-37)。在多变量分析中,TTC处于最长四分位与较差总生存期相关,但仅限于术后无肉眼残留病灶的患者。作者建议在减瘤手术后五至六周内开始辅助化疗。

要点

  • 荷兰2008-2015年4097例晚期上皮性卵巢癌患者中,初次减瘤手术1612例,中间减瘤手术2485例。
  • 中位手术至辅助化疗时间29天(IQR 24-37)。
  • 在术后无肉眼残留病灶患者中,最长四分位TTC与较差总生存期相关。

核心结论

  • 延迟开始辅助化疗是完全(中间)减瘤手术后总生存期较差的独立预后因素。
  • 作者建议在减瘤手术后五至六周内开始辅助化疗。

研究设计与样本

  • 基于荷兰癌症登记处的回顾性队列研究,纳入2008至2015年接受满意或完全减瘤手术的原发性上皮性卵巢癌(FIGO IIb-IV期)患者4097例,其中初次减瘤手术1612例、中间减瘤手术2485例。
  • TTC按四分位距分为三组:早期(<25%)、中间(25-75%)和延长(>75%),早期和延长分别与中间组比较。
  • 采用逻辑回归识别与延长TTC相关的因素,多变量Cox回归评估治疗间隔对总生存期的独立效应,初次减瘤手术和中间减瘤手术患者分别分析。

主要发现

  • 中位TTC为29天(IQR 24-37)。
  • 年龄≥65岁、完全减瘤手术、术后并发症和住院≥10天在初次减瘤手术和中间减瘤手术中均与较长TTC独立相关。
  • 与中间TTC相比,最长四分位TTC在初次减瘤手术后与较差总生存期相关(HR 1.43,95%CI 1.09-1.88),在中间减瘤手术后亦相关(HR 1.22,95%CI 1.02-1.47),但仅限于术后无肉眼残留病灶的患者。

临床怎么用

  • 作者建议在减瘤手术后五至六周内开始辅助化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to adjuvant chemotherapy (TTC) was associated with clinical outcome. METHODS: We identified all Dutch patients who received optimal or complete debulking surgery for primary EOC (FIGO IIb-IV) between 2008 and 2015 from the Netherlands Cancer Registry. TTC was divided into three groups based on the interquartile range (IQR). Early (<25%) and prolonged (>75%) TTC were compared to intermediate TTC (25-75%). Logistic regression was used to identify factors associated with a prolonged TTC and multivariable Cox regression to evaluate the independent effect of treatment interval on overall survival (OS). Patients receiving primary debulking surgery (PDS) and patients receiving interval debulking surgery (IDS) were analyzed separately. RESULTS: 4097 patients were included, 1612 underwent PDS and 2485 IDS. Median TTC was 29 days (IQR 24-37). Age ≥ 65, complete debulking surgery, postoperative complications, and hospitalization ≥10 days were independently associated with a longer TTC for both PDS and IDS. TTC in the longest quartile was associated with poor OS after both PDS (Hazard Rate (HR) 1.43, 95% CI 1.09-1.88) and NACT-IDS (HR 1.22 (1.02-1.47)) when compared to the intermediate TTC, but only in patients with no macroscopic residual disease after surgery. CONCLUSIONS: Our study provides evidence that delayed initiation of adjuvant chemotherapy is an independent prognostic factor for worse overall survival after complete (interval)debulking surgery. We advise to start adjuvant chemotherapy within five to six weeks after debulking surgery.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Timmermans M, van der Aa MA, Lalisang RI, et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol. 2018. PMID: 30001834. doi:10.1016/j.ygyno.2018.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。